Arcturus Therapeutics Holdings Inc. Common Stock
ARCTArcturus Therapeutics Holdings Inc. is a biotechnology company focused on developing next-generation RNA medicines and vaccines. Established with the aim of transforming the treatment of rare and infectious diseases, Arcturus leverages its proprietary LUNAR lipid-mediated delivery platform to enhance the efficacy of RNA-based therapeutics. The company primarily engages in research, development, and commercialization efforts within the fields of immunology, neurology, and genetic disorders.
Company News
Cathie Wood's Ark Invest made surprisingly few purchases last week, buying shares in only three companies: Figma, Arcturus Therapeutics, and 10x Genomics. Despite significant declines from their highs, Wood sees value in these growth-stage companies across design software, biotech, and genomics sectors.
Cathie Wood of Ark Invest purchased shares of Robinhood Markets, Netflix, and Arcturus Therapeutics on Wednesday, taking advantage of recent stock price dips and seeing potential growth opportunities in these companies.
Multiple health care stocks experienced significant options trading activity, with various bullish and bearish signals across different companies in the sector.
The Lipid Nanoparticles (LNPs) market is projected to grow from $1 billion in 2024 to $3.5 billion by 2034, driven by increasing demand for mRNA-based therapeutics and advances in drug delivery systems.
The global RNA therapeutics and vaccines market is projected to reach USD 940 million by 2035, growing at a CAGR of 68%, driven by advancements in RNA technologies and next-generation therapies.
